All News

Found 118 articles

• Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease

  6/17/2022

  Cyclerion Therapeutics, Inc. today announced research from preclinical studies demonstrating treatment with its lead soluble guanylate cyclase (sGC) stimulator, CY6463, was associated with improved cellular energetics and reduced inflammation in preclinical models of mitochondrial disease.

• Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium

  6/10/2022

  Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced positive topline data in its signal-seeking clinical study of CY6463.

• Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium

  6/6/2022

  Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced participation in the United Mitochondrial Disease Foundation (UMDF) Mitochondrial Medicine 2022 Symposium taking place June 8-11, 2022, in Phoenix, Arizona.

• Alkermes Announces Continued Board Refreshment, Including the Appointment of Christopher I. Wright, M.D., Ph.D. to its Board of Directors

  5/26/2022

  Alkermes plc announced a series of actions as part of its ongoing commitment to strong corporate governance and regular board refreshment.

• Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results

  5/4/2022

  Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, announced clinical development progress for CY6463, its lead program, and first quarter 2022 financial results.

• Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates

  2/24/2022

  Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, announced clinical development updates for CY6463, its lead program, and additional corporate progress.

• Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration

  2/23/2022

  Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Ariana Pharma today announced an artificial intelligence-driven, precision medicine collaboration.

• Tarsus Expands Executive Leadership Team with the Appointment of José Trevejo, M.D., Ph.D., as Chief Medical Officer

  2/3/2022

  Tarsus Pharmaceuticals, Inc., whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, announced the appointment of José Trevejo, M.D., Ph.D., as Chief Medical Officer.

• CENTOGENE Announces Nomination of Andreas Busch to Supervisory Board

  2/1/2022

  Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced the nomination of Prof. Andreas Busch as a member of the Supervisory Board, which will be proposed to the shareholders at the next General Meeting.

• Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer’s Disease with Vascular Pathology

  1/26/2022

  Cyclerion Therapeutics, Inc. today announced that patient dosing has begun in its Phase 2a study in Alzheimer’s Disease with Vascular Pathology (ADv).

• Mythic Therapeutics Launches with New Approach to Improving Antibody Drug Conjugate Performance, Backed by $103 Million in Series B Financing

  12/15/2021

  Mythic Therapeutics today announced its launch to develop smarter and safer antibody-drug conjugates (ADCs) with an oversubscribed Series B financing round of $103 million.

• Cyclerion Therapeutics to Participate in the 2021 Jefferies London Healthcare Conference

  11/11/2021

  Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, announced that management will attend the Jefferies London Healthcare Conference on Nov. 16th to 18th, 2021.

• Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update

  11/9/2021

  Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, reported today results for the third quarter 2021 and provided general corporate and pipeline updates.

• Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator Company developing lead sGC stimulator, CY6463, in multiple CNS diseases associated with cognitive impairment

  9/22/2021

  Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments that restore cognitive function, today announced a publication demonstrating that administration of a small molecule soluble guanylate cyclase (sGC) stimulator reduced markers associated with neuroinflammation in multiple preclinical models.

• Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences in September 2021

  9/8/2021

  Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, announced that Company management will present at two upcoming investor conferences.

• Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer’s Disease Summit

  8/23/2021

  Cyclerion Therapeutics, Inc. today announced participation in the Annual Biomarkers for Alzheimer’s Disease Summit taking place virtually August 25-26, 2021.

• Faze Medicines Appoints New Senior Vice President, Head of People & Culture

  8/5/2021

  Faze Medicines, a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, announced that Daryn Lewis has joined the company as Senior Vice President, Head of People & Culture.

• Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update

  7/29/2021

  Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today reported financial results for the second quarter 2021 and provided general corporate and pipeline updates.

• Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer’s Disease with Vascular Pathology at the Alzheimer’s Association International Conference 2021 (AAIC)

  7/22/2021

  Cyclerion Therapeutics, Inc. announced that it will present clinical trial design for a Phase 2a study of its lead development candidate, CY6463, in participants with Alzheimer’s disease with vascular pathology at the upcoming Alzheimer’s Association International Conference 2021.

• Beacon Biosignals and Cyclerion Therapeutics Announce Strategic Partnership

  7/8/2021

  Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Beacon Biosignals today announced an extended and expanded strategic partnership between the two companies.